About Careers MedBlog Contact us

Chinese Government To Lift Long-Standing State Controls On Drug Prices From June 1

by Bidita Debnath on May 5, 2015 at 10:08 PM
Font : A-A+

Chinese Government To Lift Long-Standing State Controls On Drug Prices From June 1

The Chinese government said on Tuesday that it will scrap long-standing state price controls on most medicines, effective June 1, as part of market-oriented reforms.

The government will no longer impose upper limits on retail prices for drugs, government agencies including the National Development and Reform Commission (NDRC) and National Health and Family Planning Commission said in a joint statement.


"The reform of drug prices needs to fully utilize the resource allocation role of the market," the statement said.

Price controls will be relaxed over drugs covered by medical insurance, blood products, immunizations, anti-AIDS and birth-control medicines, the statement said. But controls over prices of what the statement called "narcotics" as well as some psychotropic pharmaceuticals will remain, it said.

China started imposing maximum prices in 2000, but the NDRC said in a separate statement: "Rich market competition as well as stronger market supervision ability over drug prices has created the conditions to cancel the ceiling retail prices for medicine."

China has relaxed price controls in several sectors, including telecommunications, tobacco, air transport, natural gas and electricity.

Source: AFP


Recommended Reading

Latest Drug News

 India's First Urinary Incontinence Drug Launched
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
 New Ray of Hope for Atrial Fibrillation Patients With Kidney Disease
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Anti-viral Drug Bulevirtide Helps Treat Chronic Hepatitis D
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Antiviral Drug Paxlovid Linked to Lower Risk of Hospital Admission
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Price Cap Move Will Place Eli Lilly Strongly in Insulin Market
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Chinese Government To Lift Long-Standing State Controls On Drug Prices From June 1 Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests